Direct Oral Anticoagulants for Prevention of Venous Thromboembolism after Cancer-Related Surgery: Systematic Review and Network Meta-Analysis
Thrombosis and Haemostasis · 01.04.2026 · 126 (04) · 429-438
DOI: 10.1055/a-2628-3967 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.04.2026. Verfasst von Gerardo N Pititto und 3 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Residency Program, School of Medicine, University of Insubria, Varese and Como, Italy. Hauptthemen laut MEDLINE: Venous Thromboembolism, Neoplasms, Anticoagulants, Postoperative Complications. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
The risk of venous thromboembolism (VTE) is high after cancer surgery and is reduced by antithrombotic prophylaxis. We conducted a systematic review and network meta-analysis to evaluate the effectiveness and safety of direct oral anticoagulants (DOACs) for VTE prophylaxis after cancer surgery. The primary study outcome was 30-day VTE after surgery. Pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were estimated. Five randomized controlled trials (RCTs; two gynecological, one abdominal, one neurosurgical, and one thoracic; 1,694 patients) and seven observational studies (three urological, two abdominal, and two gynecological; 2,042 patients) were included. DOACs reduced the incidence of 30-day (OR 0.52, 95% CI 0.27-0.98, I2 22.7%) and 90-day VTE (OR 0.51, 95% CI 0.28-0.92, I2 0%) compared to LMWH. No difference was observed between DOACs and LMWH in 30 and 90-day bleeding outcomes. In random effect analyses, apixaban (OR 0.31, 95% CI 0.11-0.84) and not rivaroxaban reduced the risk of 30 day-VTE compared to LMWH (OR 0.69, 95% CI 0.35-1.34) without increasing the risk of bleeding at 30 or 90 days. No difference in the risk of VTE or bleeding was observed between DOACs and placebo/no treatment, but these analyses were probably underpowered. Subgroup analyses were conducted on LMWH pre-treatment, extended prophylaxis, duration of surgery, and type of surgery. Our study supports apixaban and rivaroxaban as promising alternatives to LMWH in post-operative prophylaxis of VTE after cancer surgery. Further high-quality data are needed in specific surgical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Internal Medicine Residency Program, School of Medicine, University of Insubria, Varese and Como, Italy.
- Internal, Vascular and Emergency Medicine - Stroke Unit, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.
- Department of Medicine and Surgery, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria - ASST Lariana, Como, Italy.
ORCID-Profile: Alessandro Squizzato
Zitieren
APA
Pititto, G. N., Maraziti, G., Squizzato, A., & Becattini, C. (2026). Direct Oral Anticoagulants for Prevention of Venous Thromboembolism after Cancer-Related Surgery: Systematic Review and Network Meta-Analysis. Thrombosis and Haemostasis, 126(04), 429-438. https://doi.org/10.1055/a-2628-3967
Vancouver
Pititto GN, Maraziti G, Squizzato A, Becattini C. Direct Oral Anticoagulants for Prevention of Venous Thromboembolism after Cancer-Related Surgery: Systematic Review and Network Meta-Analysis. Thrombosis and Haemostasis. 2026;126(04):429-438. doi:10.1055/a-2628-3967
BibTeX
@article{Pititto2026,
author = {Pititto, Gerardo N and Maraziti, Giorgio and Squizzato, Alessandro and Becattini, Cecilia},
title = {Direct Oral Anticoagulants for Prevention of Venous Thromboembolism after Cancer-Related Surgery: Systematic Review and Network Meta-Analysis},
journal = {Thrombosis and Haemostasis},
year = {2026},
volume = {126},
number = {04},
pages = {429--438},
doi = {10.1055/a-2628-3967}
}
EUVIMED